GoAI
Get started
Sinopharm Group Co. Ltd. logo

Sinopharm Group Co. Ltd.

1099.HK

HKSEHealthcareMedical - Distribution

Open in GoAI

Latest quote

HK$16.41

−HK$0.24 · -1.44%

Aug 24, 11:59 AM HKT

1099.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

Sinopharm Group Co. Ltd. is a prominent player in the People's Republic of China's healthcare market, specializing in the wholesale and retail of pharmaceuticals, medical devices, and related health products. The company's business activities are organized across four main divisions. Its Pharmaceutical Distribution segment supplies pharmaceutical goods to a wide range of clients, including hospitals, fellow distributors, retail pharmacies, and clinics. This division additionally offers extensive distribution, logistics, and value-added support to both domestic and international manufacturers and suppliers in the pharmaceutical and healthcare sectors. The Medical Devices segment is solely focused on the distribution of various medical equipment. Through its Retail Pharmacy division, Sinopharm manages and franchises a vast chain of drug stores, with an impressive 10,259 locations as of December 31, 2021. The "Other Business" segment is involved in the manufacturing and sale of pharmaceutical products, chemical reagents, and laboratory supplies. Beyond these core areas, the company also engages in property rental and management. It further distributes specialized items such as medical instruments, traditional Chinese herbal medicines, antibiotics, and biological products. Sinopharm provides a comprehensive array of services, including IT development, medicine and health consultations, investment services, import/export facilitation for goods and technology, various business and market information consulting, and the organization of conventions and exhibitions. Moreover, it oversees medical project investments, offers related consulting, and provides technological training. Notably, Sinopharm Group has established a strategic alliance with I-Mab to enhance its commercial capabilities and accelerate its market entry strategies. Founded in Shanghai, China, in 2003, Sinopharm Group Co. Ltd. operates as a subsidiary of Sinopharm Industrial Investment Co., Ltd.

Industry
Medical - Distribution
Sector
Healthcare
Headquarters
CN
CEO
Wanyong Lian
Listed since
Sep 23, 2009
Employees
94,910

Market position

Day range

Current HK$16.41

52-week range

Current HK$16.41

Open
HK$16.65
Previous close
HK$16.65
Volume
1.94M
0.34× average
Average volume
5.76M
Average daily volume
Market cap
51.21B HKD
Beta
0.45
Market reference 1
50-day average
HK$16.877
-2.77% below average
200-day average
HK$19.2303
-14.67% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
101.6B CNY
P/E (TTM)
6.14×
P/B (TTM)
0.52×
P/S (TTM)
0.08×
EV / EBITDA
5.27×
Earnings yield
13.11%
Free cash flow yield
22.95%
Dividend yield
4.81%

Profitability & efficiency

Gross margin
7.32%
Operating margin
2.74%
Net margin
1.24%
Return on equity
8.52%
Return on assets
1.83%
Return on invested capital
5.63%

Financial health

Debt / equity
1.29×
Current ratio
1.41×
Altman Z-score
3.89
Piotroski F-score
7 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends9%6%3%0%Gross margin, FY2021: 8.45%Gross margin, FY2022: 8.59%Gross margin, FY2023: 8.13%Gross margin, FY2024: 7.57%Gross margin, FY2025: 7.25%Operating margin, FY2021: 3.78%Operating margin, FY2022: 3.73%Operating margin, FY2023: 3.39%Operating margin, FY2024: 2.77%Operating margin, FY2025: 2.79%Net margin, FY2021: 1.49%Net margin, FY2022: 1.54%Net margin, FY2023: 1.52%Net margin, FY2024: 1.21%Net margin, FY2025: 1.24%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 8.45%. Gross margin FY2022 8.59%. Gross margin FY2023 8.13%. Gross margin FY2024 7.57%. Gross margin FY2025 7.25%. Operating margin FY2021 3.78%. Operating margin FY2022 3.73%. Operating margin FY2023 3.39%. Operating margin FY2024 2.77%. Operating margin FY2025 2.79%. Net margin FY2021 1.49%. Net margin FY2022 1.54%. Net margin FY2023 1.52%. Net margin FY2024 1.21%. Net margin FY2025 1.24%.

Income trends

Revenue

575.17B CNY-1.60%

Operating income

16.04B CNY-0.93%

Net income

7.16B CNY+1.50%
Income trends across reported periods655.52B CNY419.71B CNY183.91B CNY−51.9B CNYRevenue, FY2021: 521.05B CNYRevenue, FY2022: 552.15B CNYRevenue, FY2023: 596.57B CNYRevenue, FY2024: 584.51B CNYRevenue, FY2025: 575.17B CNYOperating income, FY2021: 19.71B CNYOperating income, FY2022: 20.6B CNYOperating income, FY2023: 20.21B CNYOperating income, FY2024: 16.19B CNYOperating income, FY2025: 16.04B CNYNet income, FY2021: 7.76B CNYNet income, FY2022: 8.53B CNYNet income, FY2023: 9.05B CNYNet income, FY2024: 7.05B CNYNet income, FY2025: 7.16B CNYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 521.05B CNY. Revenue FY2022 552.15B CNY. Revenue FY2023 596.57B CNY. Revenue FY2024 584.51B CNY. Revenue FY2025 575.17B CNY. Operating income FY2021 19.71B CNY. Operating income FY2022 20.6B CNY. Operating income FY2023 20.21B CNY. Operating income FY2024 16.19B CNY. Operating income FY2025 16.04B CNY. Net income FY2021 7.76B CNY. Net income FY2022 8.53B CNY. Net income FY2023 9.05B CNY. Net income FY2024 7.05B CNY. Net income FY2025 7.16B CNY.
Metric (CNY)FY2025FY2024FY2023FY2022FY2021
Revenue575.17B CNY584.51B CNY596.57B CNY552.15B CNY521.05B CNY
Cost of goods sold533.5B CNY540.25B CNY548.06B CNY504.71B CNY477B CNY
Gross profit41.67B CNY44.26B CNY48.51B CNY47.43B CNY44.05B CNY
Selling, general, and administrative24.02B CNY25.57B CNY26.15B CNY24.9B CNY23.2B CNY
Operating expenses25.63B CNY28.07B CNY28.3B CNY26.83B CNY24.34B CNY
Interest income500.25M CNY616.97M CNY526.21M CNY542.77M CNY558.56M CNY
Interest expense2.3B CNY2.73B CNY2.96B CNY3.52B CNY3.76B CNY
Depreciation and amortization2.03B CNY2.36B CNY4.43B CNY4.17B CNY3.92B CNY
Operating income16.04B CNY16.19B CNY20.21B CNY20.6B CNY19.71B CNY
Net income7.16B CNY7.05B CNY9.05B CNY8.53B CNY7.76B CNY

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
50%
5 beats, 5 misses, 0 met estimates
Average EPS surprise
-1.83%
10 comparable reports
Latest EPS result
1.31
Estimate 1.27 · Beat by 3.15%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates1.831.551.270.99Q4 '23MissQ2 '24BeatQ4 '24MissQ1 '25MissQ3 '25BeatQ2 '26BeatQ3 '26EstimateQ1 '27Estimate
Q4 2023, reported Oct 27, 2023: actual 1.42, estimate 1.45, surprise -2.07%, Miss. Q2 2024, reported Apr 26, 2024: actual 1.76, estimate 1.66, surprise +6.02%, Beat. Q4 2024, reported Oct 25, 2024: actual 1.28, estimate 1.48, surprise -13.51%, Miss. Q1 2025, reported Mar 20, 2025: actual 1.14, estimate 1.5, surprise -24.00%, Miss. Q3 2025, reported Aug 21, 2025: actual 1.21, estimate 1.06, surprise +14.15%, Beat. Q2 2026, reported Apr 23, 2026: actual 1.31, estimate 1.27, surprise +3.15%, Beat. Q3 2026, reported Aug 24, 2026: actual —, estimate 1.26, surprise —, Comparison unavailable. Q1 2027, reported Mar 19, 2027: actual —, estimate 1.4, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates358.63B337.25B315.86B294.48BQ4 '23BeatQ2 '24MissQ4 '24MissQ1 '25MissQ3 '25MissQ2 '26BeatQ3 '26EstimateQ1 '27Estimate
Q4 2023, reported Oct 27, 2023: actual 325.45B HKD, estimate 324.14B HKD, surprise +0.41%, Beat. Q2 2024, reported Apr 26, 2024: actual 327.19B HKD, estimate 344.84B HKD, surprise -5.12%, Miss. Q4 2024, reported Oct 25, 2024: actual 316.51B HKD, estimate 334.1B HKD, surprise -5.26%, Miss. Q1 2025, reported Mar 20, 2025: actual 308.27B HKD, estimate 314.43B HKD, surprise -1.96%, Miss. Q3 2025, reported Aug 21, 2025: actual 312.96B HKD, estimate 316.41B HKD, surprise -1.09%, Miss. Q2 2026, reported Apr 23, 2026: actual 321.76B HKD, estimate 315.53B HKD, surprise +1.97%, Beat. Q3 2026, reported Aug 24, 2026: actual —, estimate 329.05B HKD, surprise —, Comparison unavailable. Q1 2027, reported Mar 19, 2027: actual —, estimate 338.97B HKD, surprise —, Comparison unavailable.

Corporate actions

Annual dividends per share

Cash distributions grouped by calendar year; partial years are marked.

HK$0.739

2025 complete year-12.0% since 2021

2026 partial: HK$0.79

* Partial calendar year in the available dividend history.

Corporate action history

Dividend

Ex-dividend Jun 23, 2026

HK$0.79

Annual

Record Jun 24, 2026 · Payment Aug 18, 2026

Dividend

Ex-dividend Jun 16, 2025

HK$0.739

Annual

Record Jun 17, 2025 · Payment Aug 12, 2025

Dividend

Ex-dividend Jun 17, 2024

HK$0.956

Annual

Record Jun 18, 2024 · Payment Aug 13, 2024

Dividend

Ex-dividend Jun 19, 2023

HK$0.9011

Annual

Record Jun 20, 2023 · Payment Aug 14, 2023

Dividend

Ex-dividend Jun 27, 2022

HK$0.872

Annual

Record Jun 28, 2022 · Payment Aug 23, 2022

Dividend

Ex-dividend Jun 15, 2021

HK$0.8394

Annual

Record Jun 16, 2021 · Payment Aug 10, 2021

1099.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$197.4

-4.08%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.30

-3.94%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$221.8

-2.72%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$48.54

-4.82%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.14

-5.86%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$100.5

-1.86%

ETFs holding 1099.HK

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Total International Stock ETF logoVanguard Total International Stock ETFVXUS
Market value
45.26M
Weight
0.01%
AUM
646.2B USD
Expense ratio
0.05%
Price / 1D
$87.71+0.78%
Vanguard FTSE Emerging Markets ETF logoVanguard FTSE Emerging Markets ETFVWO
Market value
41.97M
Weight
0.02%
AUM
162.3B USD
Expense ratio
0.06%
Price / 1D
$60.45+0.72%
iShares Core MSCI Emerging Markets ETF logoiShares Core MSCI Emerging Markets ETFIEMG
Market value
29.2M
Weight
0.02%
AUM
160B USD
Expense ratio
0.09%
Price / 1D
$81.57+0.64%
Avantis Emerging Markets Equity ETF logoAvantis Emerging Markets Equity ETFAVEM
Market value
18.44M
Weight
0.07%
AUM
27.89B USD
Expense ratio
0.33%
Price / 1D
$94.24+0.75%
Schwab Fundamental Emerging Markets Large Company Index ETF logoSchwab Fundamental Emerging Markets Large Company Index ETFFNDE
Market value
17.02M
Weight
0.17%
AUM
10.2B USD
Expense ratio
0.39%
Price / 1D
$41.87+0.92%
Vanguard FTSE All-World ex-US ETF logoVanguard FTSE All-World ex-US ETFVEU
Market value
7.67M
Weight
0.01%
AUM
95.9B USD
Expense ratio
0.04%
Price / 1D
$85.69+0.82%
iShares MSCI Emerging Markets ETF logoiShares MSCI Emerging Markets ETFEEM
Market value
7M
Weight
0.02%
AUM
31.22B USD
Expense ratio
0.72%
Price / 1D
$67.12+0.75%
iShares MSCI China ETF logoiShares MSCI China ETFMCHI
Market value
6.94M
Weight
0.11%
AUM
6.29B USD
Expense ratio
0.59%
Price / 1D
$55.66+0.27%

Continue in GoAI

Research 1099.HK

research.disclaimer